Suppr超能文献

并非总是为时过晚:微创挽救性食管切除术 1 例报告。

It's not always too late: a case for minimally invasive salvage esophagectomy.

机构信息

Department of Surgery, Division of Minimally Invasive Surgery, UC San Diego School of Medicine, MET Building, Lower Level, 9500 Gilman Drive MC 0740, La Jolla, CA, 92093-0740, USA.

Division of Surgical Oncology, Department of Surgery, University of California, San Diego, CA, USA.

出版信息

Surg Endosc. 2021 Aug;35(8):4700-4711. doi: 10.1007/s00464-020-07937-2. Epub 2020 Sep 17.

Abstract

INTRODUCTION

Standard of care for locally advanced esophageal carcinoma is neoadjuvant chemoradiation (nCRT) and surgical resection 4-8 weeks after completion of nCRT. It is recommended that the CRT to surgery interval not exceed 90 days. Many patients do not undergo surgery within this timeframe due to patient/physician preference, complete clinical response, or poor performance status. Select patients are offered salvage esophagectomy (SE), defined in two ways: resection for recurrent/persistent disease after complete response to definitive CRT (dCRT) or esophagectomy performed > 90 days after completion of nCRT. Salvage esophagectomy reportedly has higher postoperative morbidity and poor survival outcomes. In this study, we assessed outcomes, overall, and disease-free survival of patients undergoing salvage esophagectomy by both definitions (recurrent/persistent disease after dCRT and/or > 90 days), compared to planned (resection after nCRT/within 90 days) esophagectomy (PE).

MATERIALS AND METHODS

Retrospective review of a prospectively maintained database identified patients who underwent minimally invasive esophagectomy at a single institution from 2009 to 2019. Esophagectomy for benign disease and patients who did not receive nCRT were excluded. Outcomes included postoperative complications, length of stay (LOS), disease-free survival, and overall survival.

RESULTS

97 patients underwent minimally invasive esophageal resection for esophageal carcinoma. 89.7% of patients were male. Mean age was 64.9 years (range 36-85 years). 94.8% of patients had adenocarcinoma, with 16 transthoracic and 81 transhiatal approaches. On comparing planned esophagectomy (n = 87) to esophagectomy after dCRT failure (n = 10), no significant differences were identified in overall survival (p = 0.73), disease-free survival (p = 0.32), 30-day or major complication rate, anastomotic leak, or LOS. Similarly, when comparing esophagectomy < 90 days after CRT (n = 62) to > 90 days after CRT completion (n = 35), no significant differences were identified in overall survival (p = 0.39), disease-free survival (p = 0.71), 30-day or major complication rate, LOS, or anastomotic leak rate between groups. In this comparison, local recurrence was noted to be elevated with SE as compared to PE (64.3% vs. 25.0%, p = 0.04).

CONCLUSION

Overall survival and disease-free survival were equivalent between SE and PE. Local recurrence was noted to be increased with SE, though this did not appear to affect survival. Although planned esophagectomy remains the standard of care, salvage esophagectomy has comparable outcomes and is appropriate for selected patients.

摘要

简介

局部晚期食管癌的标准治疗方法是新辅助放化疗(nCRT),并在 nCRT 完成后 4-8 周进行手术切除。建议 CRT 与手术的间隔时间不超过 90 天。由于患者/医生的偏好、完全临床反应或身体状况不佳,许多患者在这段时间内无法进行手术。选择部分患者进行挽救性食管切除术(SE),有两种定义方式:在完全缓解后的 dCRT 后(dCRT)出现复发/持续性疾病时进行切除术,或在 nCRT 完成后超过 90 天后进行切除术。据报道,挽救性食管切除术的术后发病率较高,生存结果较差。在这项研究中,我们评估了通过两种定义(dCRT 后完全缓解后的复发/持续性疾病和/或>90 天后)接受挽救性食管切除术的患者的总生存率和无病生存率,与计划的(nCRT 后/90 天内)食管切除术(PE)进行比较。

材料和方法

回顾性分析了一家机构从 2009 年至 2019 年期间接受微创食管切除术的前瞻性数据库。排除良性疾病和未接受 nCRT 的患者。主要结果包括术后并发症、住院时间(LOS)、无病生存率和总生存率。

结果

97 例患者接受微创食管切除术治疗食管癌。94.8%的患者为男性,平均年龄为 64.9 岁(范围 36-85 岁)。94.8%的患者为腺癌,其中 16 例为经胸入路,81 例为经腹入路。在比较计划的食管切除术(n=87)和 dCRT 失败后的食管切除术(n=10)时,总生存率(p=0.73)、无病生存率(p=0.32)、30 天或主要并发症发生率、吻合口漏或 LOS 无显著差异。同样,在比较 CRT 后<90 天的食管切除术(n=62)与 CRT 完成后>90 天的食管切除术(n=35)时,总生存率(p=0.39)、无病生存率(p=0.71)、30 天或主要并发症发生率、LOS 或吻合口漏率在两组之间也无显著差异。在这一比较中,与 PE 相比,SE 组局部复发率较高(64.3% vs. 25.0%,p=0.04)。

结论

SE 和 PE 的总生存率和无病生存率相当。SE 组局部复发率较高,但这似乎并未影响生存。尽管计划的食管切除术仍然是标准治疗方法,但挽救性食管切除术具有相似的结果,适用于选择的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验